
Sakar Healthcare shares opened at ₹943.50 per share today, as compared to previous close of ₹885 on Friday last week and touched an intraday low of ₹949.80 on 26 October. The stock gained 4.5% in Monday's trading session following the company's robust Q2 FY27 financial results announced on Friday. According to reports from Mint, the rally was driven by exceptional quarterly performance that significantly exceeded market expectations.
Sakar Healthcare reported a 149% year-on-year increase in net profit to ₹11.31 crore in Q2 FY27, compared with ₹4.54 crore in the corresponding quarter last year. The profit after tax (PAT) margin improved to 13% from 8% in Q2 FY26. As reported by Mint, EBITDA more than doubled, rising 114% YoY to ₹24.35 crore from ₹11.35 crore a year earlier, with the EBITDA margin expanding to 28% from 20%. Revenue from operations grew 51.88% YoY to ₹87.42 crore, compared with ₹57.56 crore in Q2 FY26. According to the latest company filing, the consolidated revenue reached ₹87.42 crore against ₹57.56 crore a year earlier, with net profit adding ₹6.77 crore year-on-year.
According to the company's press release, commercial supplies have commenced from the company's EU GMP-approved, API-integrated oncology finished dosage form facility. Additionally, Accord has received six additional EMA product site variation approvals at Sakar's oncology site, bringing the total to eight of eleven molecules. This strategic milestone strengthens the company's regulatory compliance and manufacturing capabilities in the oncology segment.
According to reports from Mint, Sakar Healthcare has delivered impressive long-term returns for investors, with the stock surging 129.42% year-to-date (YTD) and gaining 161.96% over the past one year. The stock has delivered 182.79% gains over three years, while the most impressive performance shows 503.82% returns over five years. However, the stock has witnessed mixed short-term performance, declining 17.81% over the past one month but gaining 1.12% in the past week.
As reported by Mint, Sanjay Shah, Managing Director at Sakar Healthcare, stated that Q2 FY27 has been a quarter of meaningful progress for the oncology business. The growth was driven by new oncology approvals, robust demand across geographies, an improved oncology product mix, operating leverage and disciplined cost management. For the first half of FY27, the company recorded a 134% YoY jump in net profit to ₹21.59 crore against ₹9.21 crore in H1 FY26, with EBITDA rising 90% YoY to ₹45.59 crore. The latest quarterly results show consolidated revenue of ₹87.42 crore and net profit of ₹11.31 crore, setting the top of the range for quarterly net profit over the last five quarters.